Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.49 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706888 | 0.85 | PPARG (0.46) | TRPV1RXRANR1H2NR1H3 | |
| SCHEMBL2254849 | 0.84 | RXRA (0.47) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL12361494 | 0.82 | PTGS1 (0.54) | TRPV1CYP2C9 | |
| SCHEMBL2256859 | 0.81 | CYP2C9 (0.46) | TRPV1RXRANR1H2NR1H3CYP2C9 | |
| SCHEMBL2254928 | 0.81 | RXRA (0.47) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL12871662 | 0.81 | RXRA (0.50) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL950585 | 0.80 | KLKB1 (0.52) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL3225749 | 0.79 | TGFBR1 (0.47) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL27795909 | 0.79 | RXRA (0.48) | TRPV1RXRANR1H2NR1H3NR3C2 | |
| SCHEMBL2256223 | 0.79 | PPARD (0.54) | TRPV1RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| CN-101679297-B | LXR and FXR modulators | EXELIXIS INC | 2012-01-11 | — | — | CN | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101679297-A | lxr and fxr modulators | EXELIXIS INC | 2010-03-24 | — | — | CN | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | TRPV1 1100/4885RXRA 8/4885NR1H2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.